Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model.
For the development of a safe vaccine for Alzheimer's disease (AD), we studied the immunogenicity of amyloid beta (Abeta) peptides without adjuvant. Addition of a cysteine residue (Cys) to Abeta peptides enhanced immunogenicity in mice compared to those without Cys. Vaccination with the Abeta-Cys peptides reduced Abeta deposits in AD model mice. From these results, the Abeta-Cys peptides, administered without adjuvant, are considered candidates for vaccine therapy for AD.
Matsuda
Jun-ichi
J
Applied Research Department, Kikuchi Research Center, The Chemo-Sero-Therapeutic Research Institute, 1314-1 Kawabe, Kyokushi, Kikuchi, Kumamoto 869-1298, Japan. matsuda-ju@kaketsuken.or.jp
Kaminaka
Kazuyoshi
K
Nozaki
Chikateru
C
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000544:Alzheimer Disease / Q000276:immunology / Q000628:therapy*; D023582:Alzheimer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000595:Amino Acid Sequence; D016229:Amyloid beta-Peptides / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D001921:Brain / Q000276:immunology; D003545:Cysteine / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology; D014611:Vaccination
D000276:Adjuvants, Immunologic; D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; D003545:Cysteine